Published data from randomised clinical trials is currently limited to mTOR inhibitors with everolimus, an mTOR inhibitor, being approved for treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.